Literature DB >> 52768

Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses.

A S Beare, G C Schild, J W Craig.   

Abstract

A long-term study is described of recombinant influenza viruses produced from the avirulent laboratory strain, A/PR/8/34 (H0 N1), and newly isolated H3 N2 influenza virus variants. A number of H3 H2 recombinants were found to be attenuated for man and capable of inducing antibody formation, and were therefore potentially usable as live vaccines. However, the volunteer trials as a whole suggested that, in this system, there might not be complete segregation of virulence and antigenic characteristics. No H3 N2 recombinants were detected which were non-infective for man, like the A/PR8 (H0 N1) parent, and reciprocal hybrids (H3 N1 and H0 N2) always reflected some of the virulence of the parent from which they had inherited their haemagglutinin. This property is not a feature of mouse influenza.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 52768     DOI: 10.1016/s0140-6736(75)90720-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60.

Authors:  Hong Jin; Helen Zhou; Bin Lu; George Kemble
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Illness doesn't belong to us.

Authors:  C McKevitt; M Morgan
Journal:  J R Soc Med       Date:  1997-09       Impact factor: 5.344

3.  Differential response of ferrets to infection with virulent and avirulent influenza viruses: a possible marker of virus attenuation.

Authors:  R J Fenton; R Jennings; C W Potter
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

4.  The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.

Authors:  M H Snyder; A J Buckler-White; W T London; E L Tierney; B R Murphy
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

5.  RNAs of influenza virus recombinants derived from parents of known virulence for man.

Authors:  G Florent; M Lobmann; A S Beare; N Zygraich
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

Review 6.  Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?

Authors:  Nigel J Dimmock; Andrew J Easton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

7.  Trials of live influenza A recombinants in man during natural antigenic change in 1971-1976.

Authors:  A S Beare; A P Kendal; G C Schild
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

8.  Influenza virus infection of a newborn rats: virulence of recombinant strains prepared from a cold-adapted, attenuated parent.

Authors:  M I Mahmud; H F Maassab; R Jennings; C W Potter
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

9.  Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza.

Authors:  Gary K Geiss; Mirella Salvatore; Terrence M Tumpey; Victoria S Carter; Xiuyan Wang; Christopher F Basler; Jeffery K Taubenberger; Roger E Bumgarner; Peter Palese; Michael G Katze; Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Attenuated strains of influenza A viruses do not induce degradation of RNA polymerase II.

Authors:  Ariel Rodriguez; Alicia Pérez-González; M Jaber Hossain; Li-Mei Chen; Thierry Rolling; Pilar Pérez-Breña; Ruben Donis; Georg Kochs; Amelia Nieto
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.